| Autor: |
Moreno-Sanz, Guillermo, Madiedo, Alvaro, Hernandez, Paula, Kratz, Janosch, Aizpurua-Olaizola, Oier, Brown, Matthew R. D., López, Juan R., Patiño, Jorge, Mendivelso, Fredy O. |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Pain Research. 3 |
| ISSN: |
2673-561X |
| DOI: |
10.3389/fpain.2022.854795 |
| Popis: |
To date, the therapeutic use of cannabinoids in chronic pain management remains controversial owing to the limited clinical evidence found in randomized clinical trials (RCTs), the heterogeneous nature of the clinical indication, and the broad range of cannabis-based medicinal products (CBMPs) used in both experimental and observational clinical studies. Here we evaluate patient-reported clinical outcomes (PROMS) in a cohort of adult patients, diagnosed with chronic pain of diverse etiology, who received adjuvant treatment with oral, cannabis-based, magistral formulations between May and September 2021 at the Latin American Institute of Neurology and Nervous System (ILANS-Zerenia) in Bogotá, Colombia. During this period, 2,112 patients completed a PROMS questionnaire aimed at capturing the degree of clinical improvement of their primary symptom and any potential side effects. Most participants were female (76.1%) with an average age of 58.7 years old, and 92.5% (1,955 patients) reported some improvement in their primary symptom (p < 0.001). Two monovarietal, full-spectrum, cannabis formulations containing either cannabidiol (CBD 30 mg/mL; THC |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
